Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for autoimmune diseases. However, these treatments can be limited by manufacturing, safety, and accessibility challenges. The prospect of an in vivo CAR-T cell therapy, without the need for patient cell isolation, cell culturing, and the safety risks associated with preconditioning regimens, remains a therapeutic goal.

Orna Therapeutics is a biotechnology company focused on the development of engineered circular RNA (oRNA®) and proprietary immunotropic lipid nanoparticles (LNPs). These components make up Orna’s innovative panCAR™ platform that drives CAR expression on the surface of immune effector cells after in vivo administration. In this webinar, we provide a detailed overview of this non-viral platform that results in the safe and efficient in vivo reprogramming of immune cells. We share the advantages of this technology, such as simplified production, higher protein expression, and better stability. The webinar will also include preclinical data demonstrating the utility of Orna’s anti-CD19 panCAR™ as a promising, non-viral, scalable, and tunable therapy with the potential to transform treatment of autoimmune diseases.